Cytokinetics (NASDAQ:CYTK) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Cytokinetics (NASDAQ:CYTK) had its price target lifted by Wells Fargo & Company from $95.00 to $105.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 36.52% from the stock’s current price.

Several other equities research analysts have also weighed in on CYTK. Truist Financial set a $106.00 price objective on Cytokinetics in a report on Tuesday. Stifel Nicolaus lifted their price objective on Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a report on Wednesday. B. Riley Financial lifted their price objective on Cytokinetics from $90.00 to $108.00 and gave the stock a “buy” rating in a report on Wednesday, January 21st. Morgan Stanley lifted their price objective on Cytokinetics from $90.00 to $103.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Leerink Partners reissued an “outperform” rating on shares of Cytokinetics in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.25.

Cytokinetics Stock Performance

Shares of CYTK opened at $76.91 on Thursday. The business has a 50-day moving average of $64.21 and a 200 day moving average of $63.86. Cytokinetics has a fifty-two week low of $29.31 and a fifty-two week high of $80.20. The firm has a market cap of $9.57 billion, a P/E ratio of -11.24 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, hitting the consensus estimate of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to analysts’ expectations of $8.52 million. During the same period last year, the business posted ($1.36) EPS. The company’s revenue was up 1112.5% compared to the same quarter last year. As a group, research analysts predict that Cytokinetics will post -6.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Cytokinetics news, EVP Fady Ibraham Malik sold 12,033 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $747,850.95. Following the completion of the transaction, the executive vice president owned 153,902 shares in the company, valued at $9,565,009.30. This trade represents a 7.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert I. Blum sold 36,601 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $2,274,752.15. Following the completion of the transaction, the chief executive officer owned 430,330 shares of the company’s stock, valued at approximately $26,745,009.50. This represents a 7.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 169,976 shares of company stock worth $10,710,369 in the last quarter. 2.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in Cytokinetics by 75.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 94,503 shares of the biopharmaceutical company’s stock worth $6,229,000 after purchasing an additional 40,574 shares during the period. AlphaCentric Advisors LLC boosted its position in shares of Cytokinetics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 305 shares during the last quarter. Swiss National Bank boosted its position in shares of Cytokinetics by 2.5% during the 1st quarter. Swiss National Bank now owns 229,800 shares of the biopharmaceutical company’s stock valued at $15,146,000 after acquiring an additional 5,600 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Cytokinetics by 4.8% during the 1st quarter. California Public Employees Retirement System now owns 198,530 shares of the biopharmaceutical company’s stock valued at $13,085,000 after acquiring an additional 9,129 shares during the last quarter. Finally, Assetmark Inc. boosted its position in shares of Cytokinetics by 14.5% during the 1st quarter. Assetmark Inc. now owns 3,463 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 438 shares during the last quarter.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics completed its public offering and sold 11.34 million shares, including full exercise of the underwriters’ option, raising about $805 million in gross proceeds. Article Title
• Positive Sentiment: Analysts remained constructive, with Piper Sandler and Raymond James reiterating bullish/hold views, while Wells Fargo raised its price target to $105 from $95, signaling continued confidence in the company’s longer-term outlook.
• Positive Sentiment: Coverage highlighting that Cytokinetics beat earnings expectations and that analysts have been lifting forecasts may also be helping sentiment around the stock.
• Neutral Sentiment: The company’s Q1 results presentation and offering-related disclosures keep investor attention focused on execution and pipeline development rather than any immediate operational surprise. Article Title
• Negative Sentiment: The recent stock sale increases share count and dilutes existing holders, which can pressure the stock despite the cash infusion.
• Negative Sentiment: Insider selling remains a headwind for sentiment, with an executive recently selling shares and broader insider activity showing only sales over the past several months. Article Title

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.